{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:11:45Z","timestamp":1758042705114,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bone.2020.115401","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:15:24Z","timestamp":1588284924000},"page":"115401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis"],"prefix":"10.1016","volume":"137","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bone.2020.115401_bb0005","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00198-018-4574-x","article-title":"Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation. A report of two affected families and review of the literature","volume":"29","author":"Chakhtoura","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2020.115401_bb0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/jbmr.061105","article-title":"Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23","volume":"22","author":"Frishberg","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115401_bb0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1542\/peds.99.5.745","article-title":"Hyperostosis with hyperphosphatemia. Evidence of familial occurrence and association with tumoral calcinosis","volume":"99","author":"Narchi","year":"1997","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.bone.2020.115401_bb0020","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1210\/jc.2006-0305","article-title":"The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis","volume":"91","author":"Garringer","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2020.115401_bb0025","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/jbmr.2870","article-title":"Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis\/hyperostosis-hyperphosphatemia syndrome","volume":"31","author":"Ramnitz","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0030","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.oooo.2015.05.006","article-title":"Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC)","volume":"120","author":"Vieira","year":"2015","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.12968\/denu.2012.39.6.416","article-title":"Tumoral calcinosis: a dental literature review and case report","volume":"39","author":"Krstevska","year":"2012","journal-title":"Dent Update"},{"issue":"3","key":"10.1016\/j.bone.2020.115401_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/hmg\/ddi034","article-title":"An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia","volume":"14","author":"Benet-Pages","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.bone.2020.115401_bb0045","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1172\/JCI31330","article-title":"A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis","volume":"117","author":"Ichikawa","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ng1358","article-title":"Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis","volume":"36","author":"Topaz","year":"2004","journal-title":"Nat. Genet."},{"issue":"7120","key":"10.1016\/j.bone.2020.115401_bb0055","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bone.2020.115401_bb0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"27","key":"10.1016\/j.bone.2020.115401_bb0065","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1074\/jbc.M602469200","article-title":"Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation","volume":"281","author":"Kato","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.bone.2020.115401_bb0070","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1073\/pnas.1402218111","article-title":"Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis","volume":"111","author":"Tagliabracci","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2020.115401_bb0075","doi-asserted-by":"crossref","first-page":"W452","DOI":"10.1093\/nar\/gks539","article-title":"SIFT web server: predicting effects of amino acid substitutions on proteins","volume":"40","author":"Sim","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115401_bb0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat. Methods"},{"issue":"16","key":"10.1016\/j.bone.2020.115401_bb0085","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/bioinformatics\/btv195","article-title":"PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels","volume":"31","author":"Choi","year":"2015","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.bone.2020.115401_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11154-014-9308-6","article-title":"RANKL\/OPG; critical role in bone physiology","volume":"16","author":"Martin","year":"2015","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"5","key":"10.1016\/j.bone.2020.115401_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Acmg laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.bone.2020.115401_bb0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2017.12.020","article-title":"Dialysis as a treatment option for a patient with normal kidney function and familial tumoral calcinosis due to a compound heterozygous FGF23 mutation","volume":"72","author":"Goldenstein","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.bone.2020.115401_bb0105","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/ndt\/gfu324","article-title":"Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing","volume":"29","author":"Shah","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.bone.2020.115401_bb0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.gene.2014.03.052","article-title":"A new missense mutation in FGF23 gene in a male with hyperostosis-hyperphosphatemia syndrome (HHS)","volume":"542","author":"Abbasi","year":"2014","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.bone.2020.115401_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00439-005-0026-8","article-title":"A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification","volume":"118","author":"Chefetz","year":"2005","journal-title":"Hum. Genet."},{"issue":"11","key":"10.1016\/j.bone.2020.115401_bb0120","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1210\/jc.2009-0961","article-title":"Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis","volume":"94","author":"Bergwitz","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2020.115401_bb0125","first-page":"178","article-title":"Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer","volume":"71","author":"Lammoglia","year":"2009","journal-title":"Horm. Res."},{"issue":"10","key":"10.1016\/j.bone.2020.115401_bb0130","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1210\/jc.2005-0301","article-title":"A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis","volume":"90","author":"Araya","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115401_bb0135","first-page":"1","article-title":"Lectin affinity chromatography","volume":"9","author":"Freeze","year":"2001","journal-title":"Curr. Protoc. Protein Sci."},{"issue":"5","key":"10.1016\/j.bone.2020.115401_bb0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bone.2020.115401_bb0145","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00198-019-04996-7","article-title":"High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis","volume":"30","author":"Rupp","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2020.115401_bb0150","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00198-014-2719-0","article-title":"Characterizing microarchitectural changes at the distal radius and tibia in postmenopausal women using HR-pQCT","volume":"25","author":"Kawalilak","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115401_bb0155","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2006-1825","article-title":"Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations","volume":"92","author":"Ichikawa","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0160","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/en.2008-0877","article-title":"Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression","volume":"150","author":"Ichikawa","year":"2009","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.bone.2020.115401_bb0165","doi-asserted-by":"crossref","first-page":"E929","DOI":"10.1152\/ajpendo.90456.2008","article-title":"Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis","volume":"295","author":"Garringer","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115401_bb0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2015.11.015","article-title":"FGF23-S129F mutant bypasses ER\/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients","volume":"93","author":"Shawar","year":"2016","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0175","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ajmg.a.36476","article-title":"Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms","volume":"164A","author":"Finer","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"4","key":"10.1016\/j.bone.2020.115401_bb0180","doi-asserted-by":"crossref","first-page":"247S","DOI":"10.1016\/8756-3282(95)00019-A","article-title":"Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide","volume":"16","author":"Yamaguchi","year":"1995","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2020.115401_bb0185","first-page":"1691","article-title":"Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis","volume":"33","author":"Nakamura","year":"2006","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.bone.2020.115401_bb0190","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates, pharmacology and use in the treatment of tumour-induced hypercaicaemic and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bone.2020.115401_bb0195","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s00198-018-4639-x","article-title":"Bisphosphonate therapy in an infant with generalized arterial calcification with an ABCC6 mutation","volume":"29","author":"Akhtar Ali","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2020.115401_bb0200","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1038\/s41598-018-24228-y","article-title":"Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation","volume":"8","author":"Bauer","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bone.2020.115401_bb0205","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2017.12.062","article-title":"Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum","volume":"71","author":"Kranenburg","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.bone.2020.115401_bb0210","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/jbmr.157","article-title":"A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover","volume":"25","author":"Burghardt","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115401_bb0215","first-page":"45","article-title":"Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man","volume":"49","author":"Walton","year":"1975","journal-title":"Clin. Sci. Mol. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:49:02Z","timestamp":1757612942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":43,"alternative-id":["S8756328220301812"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115401","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115401"}}